China will launch a new round of investigation into bribery of pharmaceutical companies

Phoenix Financial News Beijing time on the afternoon of August 14, Reuters quoted Xinhua news agency as saying that China will start a new three-month investigation on Thursday to regulate the rampant bribery in the field of medicine and medical devices Today (14) afternoon, Xinhua News Agency issued a document saying that the State Administration for Industry and Commerce will carry out special treatment of unfair competition nationwide The article indicates that commercial bribery not only leads to the false high price, destroys the market order of fair competition, but also destroys social morality and industry atmosphere The State Administration for Industry and commerce requires the industrial and commercial organs at all levels to focus on the industries and fields related to the vital interests of the people, such as the purchase and sale of medicine, medical services, school selection and promotion, and severely investigate and deal with commercial bribery in the process of bidding According to the report, the purpose of the investigation by the China Administration for Industry and commerce is to eliminate bribery, fraud and other anti competitive behaviors in various fields Xinhua said the Administration for Industry and commerce would impose severe penalties on bribery in the bidding process for medicine and medical services At the same time, the national development and Reform Commission has investigated 60 overseas and domestic pharmaceutical companies on drug pricing, which is not over yet Chinese police have stepped in to investigate the bribery of GlaxoSmithKline, a Chinese pharmaceutical company, and GSK has admitted that some Chinese executives seem to have violated Chinese laws In addition, Chinese health ministry officials are also investigating the bribery of Sanofi, a French pharmaceutical manufacturer, which Sanofi "attaches great importance to".